Drugs / ETALOCIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00006375 | Jun 2000 → Feb 2003 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00069875 | Sep 2003 → Dec 2005 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00055250 | Jan 2003 → Oct 2005 | malignant pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETALOCIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL329123 ↗ |
| Known as | LY-193111 | ChEMBL registry synonym — accepted as the source's own label CHEMBL329123 ↗ |
| Known as | LY293111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069875 ↗ |
| Known as | VML 295 | ChEMBL registry synonym — accepted as the source's own label CHEMBL329123 ↗ |
| Action | Activate | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL329123 ↗ |
| Action | Inhibit | “Leukotriene B4 receptor 1 antagonist” CHEMBL329123 ↗ |
| Modality | Small molecule | — CHEMBL329123 ↗ |
| Route | Oral | “Patients receive oral LY293111 twice daily.” NCT00006375 ↗ |
| Target | LTB4R | “Leukotriene B4 receptor 1 antagonist” CHEMBL329123 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL329123 ↗ |